蛋白酶体抑制剂carfilzomib(商品名:Kyprolis)于2012年7月获美国FDA批准,用于治疗已使用过包括硼替佐米和免疫调节药物在内的2种以上治疗方案,但在60 d内疾病仍有进展的多发性骨髓瘤患者。药理研究表明:该药可与20S蛋白酶体的含苏氨酸N-末端活性位点可逆性结合。在用实体瘤 The proteasome inhibitor carfilzomib (trade name: Kyprolis) was approved by the U.S. FDA in July 2012 for the treatment of more than two treatment regimens that have been used, including bortezomib and immunomodulatory drugs, but the disease There are still multiple myeloma patients. Pharmacological studies have shown that this drug reversibly binds to the threonine-N-terminal active site of the 20S proteasome. With solid tumors